(PRWEB) October 27, 2002
EAST LONGMEADOW, MA; 21 October, 2002: With the purchase of Quantanova, Ltd., biolitec AG now manufactures the therapeutic drug FoscanÂ®, used to treat cancer in the head and neck area, at its new facility, biolitec Pharma. The photosensitizer, only available outside the United States, is produced at Callanish on the Isle of Lewis, Scotland, a location that is also famous for its 6000 year old Standing Stones.
Foscan has been approved by the European Drug Regulation and the European Commission and is produced in biolitecÂs new facility in Scotland. Activated by the red light emitted from biolitecÂs 652 nm PDT laser, Foscan is a compound that selectively targets tumor cells and provides gentle treatment for head and neck cancer. To date, over 1200 patients have undergone this treatment.
biolitecÂs new facility not only produces Foscan, but also has the capacity to research and development of new chemical compounds for photodynamic therapy (PDT). biolitec Pharma consists of chemists and quality assurance professionals.
For more information, please call biolitec at 800-934-2377 or visit http://www.biolitec.com. For further information on Foscan, please contact biolitec Pharma directly: +44 1786 458860.
About biolitec, Inc.
Established in 1987, biolitec, Inc. manufactures advanced lasers and fiber optic delivery systems for medical and dental applications. Its strength as a vertically integrated manufacturer enables the production of top quality lasers, fibers, handpieces, and accessories Â as well as ongoing research into new medical breakthroughs such as photodynamic therapy (PDT).
515 Shaker Rd.
East Longmeadow, MA 01028